Veru Reports Third Quarter Fiscal 2022 Financial Results; Progresses Sabizabulin Treatment for COVID-19 Towards Regulatory Decisions in Key Territories

Go back to Veru Reports Third Quarter Fiscal 2022 Financial Results; Progresses Sabizabulin Treatment for COVID-19 Towards Regulatory Decisions in Key Territories
(NASDAQ: VERU) Delayed: 3.04 +0.08 (2.70%)
Previous Close $2.96    52 Week High
Open $2.91    52 Week Low
Day High $3.07    P/E N/A 
Day Low $2.91    EPS
Volume 344,774